Optical methods have revolutionized medical diagnoses, therapies and research, and have penetrated many medical disciplines for example, tumor diagnosis and treatment. Tumor recurrence and metastasis are the major obstacles for long-term survival in cancer. The metastasis is reported to be correlated with the presence of circulating tumor cells (CTCs) in the vasculature as a consequence of either advanced tumor growth and invasion, or a therapeutic intervention. Thus, CTCs are considered to be important biomarkers for cancer progress and prognosis. The quantification of CTCs is an emerging tool used to diagnose, stratify and monitor patients with metastatic diseases. A number of methods have been developed to detect CTCs, some of which have been applied in clinical diagnosis. However, conventional methods are restricted by invasiveness, lower sensitivity caused by small blood sample volumes, and difficulty in recording the dynamics of CTCs. A novel technique named in vivo flow cytometry (IVFC) can overcome those restrictions. IVFC, which was invented in 2004, can quantitatively monitor circulating cells in vivo , both noninvasively and dynamically. Our work has demonstrated that IVFC has higher specificity and sensitivity than conventional methods. A number of outstanding studies by IVFC have been published on cancer including leukemia, prostate cancer, breast cancer, hepatocellular carcinoma and melanoma, and others. However, there are still numerous remaining questions about cancer metastasis which could be investigated using IVFC. IVFC is a novel and powerful technique to elucidate mechanisms that drive hematogenous metastasis and to monitor the efficacy of cancer therapy. With advances in the technique, IVFC could potentially be used clinically in both cancer diagnosis and treatment. The present review gives an overview of this topic. 
Introduction
Light has been used for treatment of illness for thousands of years. However, it has only been since the invention of the laser about 50 years ago that the potential of light in medicine has really been revealed. Several kinds of optical methods have been used in illness diagnoses, therapies and research, such as endoscopy [1] , photodynamic therapy [2] and optical cellular/molecular imaging methods [3] . They have revolutionized medicine and have penetrated most disciplines, for example tumor diagnosis and treatment. Researchers continue to push the boundaries so that tumor diagnoses and treatments are faster, safer, less invasive, more precise, and more effective.
Tumor recurrence and metastasis are the major obstacles for long-term survival in cancer. Hematogenous spreading of circulating tumor cells (CTCs) from the primary tumor is a crucial step in the metastasis cascade, which leads ultimately to the formation of overt metastases [4] . Recent studies have shown that the number of CTCs is an independent predictor of progression-free survival and overall survival in metastatic breast cancer and metastatic colorectal cancer [5, 6] . However, it remains unclear whether the number of CTCs is associated with disease progression and treatment response in other types of cancer.
It has been more than a century since the seed and soil hypothesis [7, 8] was proposed. Here we review the history of the evolvement of this theory and show that CTC, the seed, is an important biomarker for cancer progress and prognosis, especially metastasis, and important to cancer diagnosis [5, 6] . Many methods based on blood extraction have emerged, some of which have been used in clinic [5, 9 -14] . However there are restrictions in those in vitro methods, which could be overcome by a novel technique, the " in vivo flow cytometry " (IVFC) [15 -17] . IVFC has enormous advantages in detecting CTCs and the study of cancer metastasis [18 -23] . It provides a new horizon in cancer study and clinical diagnosis.
The seed and soil hypothesis
Metastasis refers to the processes that involve the spread of tumor cells to other tissue or organs, both near to as well as distant to the original site. Then the spreading tumor will grow to form metastatic tumors and lead to a recurrence of the cancer (Figure 1 ). This phenomenon makes cancer hard to overcome and is the cause of most cancer deaths. Therefore, understanding the pathogenesis of metastasis on the systemic, cellular and molecular levels are important goals of cancer research.
It has been more than a century since Paget [7] proposed the seed and soil hypothesis to describe the mechanism by which cancer spreads or metastasizes throughout the body. This hypothesis is the most popular theory to explain the mechanism of metastasis. In Paget ' s studies, he was the first to find out that metastasis was not due to chance but that certain tumor cells had specific affinity for the milieu of certain organs. Thus, he visualized the spreading tumor cells as " seeds " and targeting organ as " soil " . He concluded that metastases formed only when the seed and soil were compatible.
In 1929, Ewing [24] challenged the hypothesis and considered metastasis to be purely due to mechanical factors, such as the structure of the blood vessels. Since the 1970s, the selective characteristics of metastasis have been demonstrated [25 -27] . In the past few decades more evidence has emerged regarding the interactions between CTCs (the " seeds " ) and specific organ ' s microenvironment (the " soil " ) [27, 28] . Selective metastasis is influenced by the characters of both the seeds [28 -30] and the soil [31, 32] . For example, there are complex interactions between leukemia and the microenvironment of bone marrow in the process of metastasis [19, 33] .
In 2003, Fidler [8] amended this hypothesis accordingly. In his opinion, the " seed and soil " hypothesis consists of three principles: -First of all, tumors (both primary tumor and metastases) consist of both tumor cells and host cells, which include epithelial cells, fibroblasts, endothelial cells and infiltrating leukocytes. Moreover, tumors are biologically heterogeneous and contain genotypically and phenotypically diverse subpopulations of tumor cells, each of which have the potential to complete some steps in the metastatic process, but not all. -Secondly, the process of metastasis is selective for tumor cells. The successful metastatic cell (the " seed " ) must be proficient in all events which include invasion, embolization, survival in the circulation, arrest in a distant capillary bed, and extravasation into and multiplication within the organ parenchyma, rather than just a few. Although some of the steps in this process contain stochastic elements, as a whole metastasis favors the survival and growth of a few subpopulations of cells that preexist within the parent tumor. Thus, metastases can have a clonal origin whereas different metastases can originate from the proliferation of different single cells. -Thirdly, and perhaps the most important principle for the design of new cancer therapies is that metastases can only develop in specific organs. The microenvironments of different organs (the " soil " ) are biologically unique. Endothelial cells in the vasculature of different organs express different cellsurface receptors and growth factors that influence the phenotype of metastases that develop there. In other words, the outcome of metastasis depends on multiple interactions ( " cross-talk " ) of metastasizing cells with homeostatic mechanisms, which the tumor cells can usurp.
Circulating tumor cellsthe important biomarker for metastasis
Biomarkers of metastasis are very important in cancer diagnosis, treatments and studies. Investigators have been interested in the search for biomarkers of metastasis for some time [4 -6, 9, 34 -37] . However, the current routine of clinical manifestation, radiological evaluations, and serum tumor markers are not capable of providing enough information about the ongoing metastasis early enough, or predicting the clinical outcome with high accuracy and reproducibility [4] . As described above, both the seeds and the soil are important to metastasis. CTCs, i.e., " the seeds " , are defined as tumor cells originating from either primary sites or metastases and circulating freely in the peripheral blood of patients and are extremely rare in healthy people [38] . CTCs have long been considered a reflection of tumor aggressiveness. Tumor-induced angiogenesis occurs in step with the action of invasion, which gives rise to the possibility that highly invasive but localized tumors may unleash CTCs into peripheral circulation before any bona fide metastases have been established. Highly aggressive CTCs may not only establish metastases in distant organs but are also capable of self-seeding back to their original organs [39] . Testing for CTCs has emerged as a new and promising tool for stratifying and monitoring patients with metastatic disease [11] . A number of currently available CTCs detection platforms have been verified in various clinical settings, which strongly suggest that CTCs detection has enormous potential in assisting malignancy diagnosis, estimating prognosis and monitoring the response of the anticancer therapy [40] . According to previous studies, CTCs count could be used as a potential and powerful biomarker for cancer diagnosis and prognostic prediction [4, 5] , in e.g., colorectal cancer [41, 42] , gastric cancer [43, 44] , liver cancer [45] , lung cancer [46, 47] , breast cancer [5, 6, 9 -14] , and prostate cancer [48] .
Conventional methods to detect CTCs
Conventional methods to detect CTCs are based on the analysis of blood samples and have been used in clinical assays [40] . The methods can be classified into two approaches: (1) immunological assays using monoclonal antibodies directed against histogenic proteins and (2) polymerase chain reaction (PCR)-based molecular assays exploiting tissue-specific transcripts. Before application of the detection technology, most approaches require an enrichment of CTCs. Enrichment can improve the sensitivity and is usually based on density-gradient centrifugation and immunomagnetic procedures [49] .
In immunological approaches, a number of monoclonal antibodies are used for protein markers of cancer cells. The most widely used system for immunological assays is called CellSearch TM [5, 13] , which has been also used frequently in clinical research. It is an automated immunomagnetic enrichment and staining system. In this approach, CTCs are enriched by ferrofluids coupled to antibodies against an epithelial cell adhesion molecule (EpCAM). EpCAM is a cell adhesion molecule commonly expressed on normal epithelial cells (usually not present in the blood of healthy subjects) and malignant epithelial cells [50, 51] . Furthermore, tumor cells are identified by cytokeratin (cytoskeletal proteins that are specifically expressed in epithelial cells) staining using fluorescent antibodies. Non-specific staining of hematopoietic cells is detected by counterstaining with cluster of differentiation 45 (CD45) (common leukocyte antigen) antibodies. In addition to CellSearch TM , many other immunological assays have been developed. For example, fluorescence activated cell sorting analysis using conventional flow cytometry [18, 23] , high throughput CTC chip [52, 53] , fiber-optic array scanning technology [54, 55] , etc.
PCR assays have been used in CTCs detection since the 1990s [56] . These methods have a higher sensitivity [57] . In all these methods, quantitative real-time PCR (qPCR) has addressed the problem of false-positive signals in noncancer controls [58] . However, in view of the lack of true cancer specific molecular targets, qPCR has become more or less the state-of-the-art quantitative method, allowing the determination of cut-off values of marker transcript numbers in samples of non-cancer controls, by which transcripts can be considered as tumor cell-derived [40] .
However, all these conventional methods are limited by invasiveness, lower sensitivity caused by limited blood sample volumes, and the difficulty to record the dynamics of CTCs. As a result noninvasive, more sensitive and dynamic monitoring methods are still needed. 
In vivo flow cytometry and CTCs detection
Optical imaging methods, such as in vivo imaging technology in small animal [59] , intravital/endoscopic microscopy [19, 60] , confocal/multi-photon microscopy, optical coherence tomography [61] , and photoacoustic imaging [62] , are widely used in cancer diagnosis and research as they have the advantage of being noninvasive, highly sensitive and of high resolution. However, none of the methods is optimized to quantitatively detect changes in the number of circulating cells as IVFC does. IVFC was invented in 2004 [15] . It is a novel technique that can monitor circulating cells in vivo , and combines the advantages of conventional flow cytometry with in vivo confocal microscopy ( Figure 2 ). In this technique the laser is focused on a slit. With imaging guidance, the slit is positioned to cover the natural regions of blood flow which could be arteries, veins or lymphatic vessels ( Figure 3 ). When target cells, which are usually acquired real-time information may provide novel insights into tumor progress, metastasis processes and the response to treatment. It can improve our knowledge of tumor metastasis and guide therapeutic schedules. In 2004, Georgakoudi and her coworkers [20] were the first group to use IVFC to study cancer. They presented the depletion kinetics of injected prostate cancer cells in mice and indicated that IVFC might become a new method for enumerating CTCs. They found out that the depletion kinetics of CTCs showed differences among different tumor cell lines and host animals. This might indicate that metastasis is associated with the characters of both tumor cells and hosts. In addition, the real-time changes of depletion kinetics might provide novel information about tumor metastasis, e.g., real-time processes of CTCs forming, homing or re-emerging. In 2011, Li et al. [22] in our group provided depletion kinetics of injected prostate cancer cells with different metastasis potential. We found out that the CTCs depletion kinetics might be associated with the condition of metastatic sites.
In 2005, Sipkins and her coworkers [19] published important work about IVFC, which firstly used IVFC to study the CTCs homing and the interaction between " seed " and " soil " in tumor metastasis. In this study, they initially used IVFC to evaluate the drug effect to restrain bone marrow metastasis of leukemia. An important pair of molecules for bone marrow metastasis was discovered, namely C-X-C chemokine receptor type 4 (CXCR4) and stromal cellderived factor 1 (SDF-1). The inhibitor of CXCR4 was able to significantly restrain CTC depletion and homing to bone marrow. In this work, IVFC provided important evidence and demonstrated its importance in cancer study. A similar method was used in the studies of multiple myeloma [68 -70] , prostate cancer [22] , and others.
Our group focused on liver cancer study using IVFC. We studied the depletion kinetics of injected liver cancer cells with different metastasis potential [21, 22] . However, the injection tumor model, which has been commonly used by many groups before, could not mimic metastasis well. Although it reflected some circulating metastatic characteristics or therapeutic responses of cancer cells, the large number of injected CTCs does not exist in pathologic conditions [71, 72] . Thus, we built an orthotopic hepatocellular carcinoma (HCC) model and combined it with IVFC to study cancer metastasis [23] . It was the first study of CTCs dynamics using a clinically relevant oncology condition by IVFC. Interestingly, we observed significant differences in the CTCs dynamics between orthotopic and subcutaneous models. We also used our model to investigate whether liver resection promoted or restricted hematogenous metastasis in advanced HCC. Both the labeled with fluorescence, are flowing with the blood and pass the slit, the fluorescence signal is excited and is subsequently detected by a confocused photomultiplier tube. The data can be collected and recorded by computer and analyzed by software (Figure 4 ) . A line-separating method has been used conventionally to derive CTCs counts from the IVFC data [20] . Other optimized methods, such as a wavelet-based method [22] , have also been developed in data processing of IVFC. The technique is capable of continuously monitoring the varieties of target cells in circulation, e.g., cancer cells [18 -23] , hematopoietic stem cells [63, 64] , lymphocytes [65, 66] , red blood cells [15 -17] , apoptotic cells [67] , and yields quantitative results without affecting the physiology of the subject.
Compared to conventional CTCs detection methods, IVFC has the advantage of noninvasiveness, higher sensitivity and dynamic monitoring. In our opinion, the most important advantage of this technique is dynamic monitoring. The number of CTCs and early metastases decreased significantly after tumor resection. Resection also prominently restricted hematogenous and distant metastases. Importantly, CTCs numbers were correlated with tumor growth in the orthotopic tumor model, including the number and size of distant metastases. Our work has demonstrated that when combined with orthotopic tumor models, the novel IVFC technique offers the capability to elucidate mechanisms that drive hematogenous metastasis and to monitor the efficacy of cancer therapy.
He et al. [18] and Galanzha et al. [73, 74] introduced multiphoton, photoacoustic and photothermal techniques into IVFC. Meanwhile, they used a monoclonal antibody to label and detect CTCs. As reported, they succeeded in detecting rare CTCs in subcutaneous lung cancer or melanoma model. Moreover, Alt et al. [75] designed a retinal flow cytometer which is an improved IVFC and can detect circulating cells in retinal vessels. This technique had a five times higher sensitivity than conventional IVFC and provided a suitable site for detection which could also be used in clinic. These might enable the use of IVFC in clinical diagnosis or therapeutic evaluations.
There are two disadvantages of IVFC which could limit its further applications. Firstly, IVFC when used as an optical method has a limited detection depth. Only superficial vessels, such as vessels in mouse ear or retinal vessels, can be used directly for measurements. An endoscopic IVFC might be useful for the clinical use. Photoacoustic flow cytometry might also be useful in detecting deeper vessels. Secondly, the labeling of target cells is a problem, especially for clinical applications. The specific labeling of various tumor cells currently presents a big challenge for use in medicine, and this limits the applications of IVFC in clinical diagnoses or therapeutic evaluations. Therefore, studies of novel probes which specifically target tumor cells will be significant for further IVFC clinical applications. Moreover, label-free IVFC, which can detect tumor cells without labeling, could also be a promising development.
Discussion
We describe here the use of IVFC as a noninvasive and continuous method to monitor the dynamics of CTCs in cancer metastasis. Conventional methods such as conventional flow cytometry or methods based on magnetic bead sorting followed by immune-staining and fluorescence imaging [5, 9 -14] can quantify CTCs in vitro . However, it is difficult to monitor CTCs dynamics using these methods. In contrast, IVFC has been optimized to quantitatively detect changes in the number of CTCs noninvasively, and can detect rare CTCs by prolonging the time of measurement. In our study [23] , IVFC had about ∼ 1.8-fold higher sensitivity than whole blood analysis by conventional flow cytometry. This improvement may be caused by absence of the loss from extract and treatment of blood sample.
There are three major advantages for IVFC: (1) Noninvasiveness. This advantage might be important to patients in the clinic. Furthermore, for scientific research, this advantage may guarantee the survival of animals compared to conventional methods. (2) Higher sensitivity. Without the processes of blood extraction and sample treatment, the factitious error and sample loss can be avoided. Moreover, the sensitivity of conventional methods is restricted by sample volume. This restriction can be resolved by prolonging IVFC testing time. (3) Dynamic monitoring. IVFC could monitor the CTCc dynamics in real-time and in the same proband, which is, to our knowledge, currently impossible for conventional methods. If by increasing the time points of sampling to approximate real time, the volume of the samples will be restricted by that of the proband ' s whole blood, and the sensitivity will be greatly compromised.
Conclusion
In conclusion, the novel IVFC technique offers the possibility of monitoring rare CTCs, elucidate mechanisms that drive hematogenous metastasis and evaluate the efficacy of cancer therapy. IVFC may provide new insights in scientific research and future clinical applications.
